Form 4 for PFE Pfizer
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001225208-22-003465 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-25 | 2022-02-23 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | M - OptEx | $27.34 | +11.7K | 21.7K | +118% | +$321.2K |
| D | 2022-02-25 | 2022-02-24 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | A - Grant | $0.00 | +2,893 | 16.4K | +21% | $0 |
| DM | 2022-02-25 | 2022-02-23 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | F - Tax | $50.01 | -8,154 | 13.5K | -38% | -$407.8K |
| DM | 2022-02-25 | 2022-02-24 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | A - Grant | $0.00 | +21.8K | 11.6K | New | $0 |
| D | 2022-02-25 | 2022-02-23 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | M - OptEx | $0.00 | -11.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | M | A | 11,748 | $27.34 | 21,668 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 2 | Common | Common Stock | 2022-02-24 | A | A | 2,893 | $0.00 | 16,407 | D | — | — | (F5) The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. |
| 3 | Common | Common Stock | 2022-02-23 | F | D | 2,339 | $46.87 | 19,329 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 4 | Common | Common Stock | 2022-02-23 | F | D | 5,815 | $51.28 | 13,514 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 5 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 10,222 | $0.00 | 10,222 | D | $45.96 · 2029-02-24 to 2029-02-24 | 10,222 Common Stock | (F7) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
| 6 | Derivative | Stock Appreciation Rights | 2022-02-23 | M | D | 11,748 | $0.00 | 0 | D | $27.34 · 2022-02-23 to 2022-02-23 | 11,748 Common Stock | |
| 7 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 11,623 | $0.00 | 11,623 | D | $45.96 · 2027-02-24 to 2027-02-24 | 11,623 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |